

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification 5 : C08F 8/14, 8/30, C07L 29/02 C07L 29/10</p>		A1	<p>(11) International Publication Number: WO 92/22591 (43) International Publication Date: 23 December 1992 (23.12.92)</p>		
<p>(21) International Application Number: PCT/US92/05046 (22) International Filing Date: 9 June 1992 (09.06.92)</p>		<p>(81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), MC (European patent), NL (European patent), SE (European patent).</p>			
<p>(30) Priority data: 715,561 14 June 1991 (14.06.91) US</p>		<p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>			
<p>(71) Applicant: RESEARCH & DIAGNOSTIC ANTIBODIES [US/US]; P.O. Box 8300, Berkeley, CA 94707 (US). (72) Inventors: WEBBER, Robert ; PAI, Mohandas ; P.O. Box 8300, Berkeley, CA 94707 (US). (74) Agent: BIELEN, PETERSON & LAMPE; 1990 N. California Blvd., Suite 720, Walnut Creek, CA 94596 (US).</p>					
<p>(54) Title: POLYMERIC RESIN FOR PEPTIDE SYNTHESIS</p>					
<p>(57) Abstract</p> <p>A polymeric resin for the preparation of peptides utilizing a polymeric matrix such as polystyrene-divinylbenzene copolymer. A vanillyl alcohol (HMBA), Trityl alcohol, or Trityl Amine group is attached to the polymeric carrier for use in the building polypeptides by solid phase peptide synthesis employing the Fmoc protecting strategy.</p>					

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	ML	Mali
AU	Australia	FR	France	MN	Mongolia
BB	Barbados	GA	Gabon	MR	Mauretania
BE	Belgium	GB	United Kingdom	MW	Malawi
BF	Burkina Faso	GN	Guinea	NL	Netherlands
BG	Bulgaria	GR	Greece	NO	Norway
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	RO	Romania
CA	Canada	IT	Italy	RU	Russian Federation
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark	MG	Madagascar		

POLYMERIC RESIN FOR PEPTIDE SYNTHESIS
BACKGROUND OF THE INVENTION

The present invention relates to a novel polymeric resin and method suitable for use in creating polypeptides.

Solid phase peptide synthesis (SPPS) has proven to be the only practical method of producing synthetic peptides longer than 8-10 amino acids. One method of producing synthetic peptides is called Boc (tert-butyloxycarbonyl) SPPS. Another method of producing synthetic peptides is known as Fmoc (9-fluorenylmethoxy carbonyl) SPPS. Both Boc and Fmoc SPPS employ minuscule spheres of specially produced resin which are suspended in a chemical solution. Each of these spheres serve as a anchor for the assembly of amino acid chains to produce polypeptides.

The Boc SPPS, although the most popular currently used method for the synthesis of peptides, suffers from low yield of product (especially with peptides of medium to long length), low purity, and an inability to build certain combinations of the amino acids except with great difficulty and expense. Specifically, trifluoroacetic acid (TFA), normally used to deprotect the amino terminal during each synthesis cycle in the Boc protection strategy, also cleaves approximately 1% of the resin anchor peptides from the resin spheres. Thus, yield and purity diminishes rapidly during the synthesis processes. The latter is a result of cleaved and lost chains leaving free initiation sites on the resin, thus permitting new chains to start building thereupon. Moreover, hydrofluoric acid (HF), an integral component of Boc SPPS, is responsible for many destructive side effects when applied to synthetic peptides.

Fmoc SPPS improves upon Boc SPPS in that an orthogonal synthesis system is employed. In other words, the side-chain blocking groups and the peptide-resin linkages are completely stable to the agents used during each step of the synthesis of peptides. Specifically, the deprotecting step of each cycle employs a secondary amine base which does not attack the bond between the growing peptide chain

and resin support, since this bond is acid labile. Moreover, only TFA is used with Fmoc, eliminating the destructive side effects of HF. Some Fmoc SPPS, however, employs polyamide resin which generally possesses a low loading capacity. Present polyamide resins also tends to clump together rendering it impotent for large scale production.

Reference is made to United States Patent 4,831,084 and 4,914,151 to Mergler et al which describes polystyrene resin-linker formulations which are usable in Fmoc SPPS. Unfortunately, the resin described in Mergler is difficult to prepare since the starting material must made by a multi-step reaction. In addition, the finished synthetic peptide is cleaved from the resin employing 1% TFA in dichloromethane (DCM). It has been found that 1% TFA is strong enough to remove a significant fraction of the side chain blocking groups, either Boc or triphenylmethyl (Trt). Boc is used to block the functional moiety on the side chains of the Lys, while Trt blocks Cys and His. Elimination of these amino acids from any peptide construction severely hinders applicability of the same. Also, the Mergler resin generally operates at a low level of substitution, thus, precluding large scale industrial processing. Making such resin with high loading characteristics, would be enormously costly since a starting material for this resin is expensive.

Other resins developed for the production of protected peptide segments or fragments by Fmoc-SPPS were susceptible to similar problems. Most notably, prior resins flaws include the irreversible attachment of tryptophan to the support resin and the alkylation of various amino acids when the product is being cleaved from the solid support matrix.

There has been a continuing need for resins usable in Fmoc SPPS which result in higher yields, and higher purity, and which are applicable to the building of all sequences of both naturally occurring and unnatural amino acids, as

well as other molecules containing carboxylic acids moieties.

SUMMARY OF THE INVENTION

The present invention provides three resins each of which provides a unique functional handle unto which protected amino acids and other molecules possessing a free carboxylic acids moiety can be attached.

The first resin (Resin #1) takes the formula of 4-hydroxy-3-methoxy-benzoyl alcohol (HMBA) attached to a polystyrene-dvb copolymer and is a general purpose resin for routine Fmoc-SPPS. It is far less expensive to produce than the standard p-alkoxy benzoyl alcohol resin used for Fmoc-SPPS since the starting material, vanillyl alcohol is readily and inexpensively available in large quantities. The finished synthetic peptide can be cleaved from the resin using 25% TFA in dichloromethane (DCM) which is a significant improvement over the 95% TFA required to cleave products from p-alkoxy benzoyl alcohol resin. The HMBA resin may be derivatized or loaded with an amino acid or other carboxylic acid containing molecule.

The second resin (Resin #2) may be termed trityl alcohol attached to a polystyrene-dvb matrix. The second resin is a very dilute acid susceptible resin for the production of protected peptide fragments by Fmoc-SPPS. The finished protected peptides are cleaved from the support matrix with 15% acetic acid and 85% DCM. The elimination of TFA during this desirable cleaving step is a significant, and unexpected property of Resin #2. The level of substitution of the starting material and the yield of synthetic peptides using such material is quiet high.

The third resin (Resin #3) is specifically designed for the production of peptide amides by Fmoc-SSPS. Resin #3 is a trityl amine linked to a polystyrene-dvb matrix. Such trityl amine resin may be loaded with an amino acid and employed in peptide synthesis using the Fmoc-SSPS strategy. The trityl amine resin may also be loaded with other carboxyl acid containin molecules to yield carboxyl amides. The peptide amide may be cleaved from the resin

using 25% TFA in DCM without multistep syntheses of linker intermediates.

It may be apparent that a novel and useful group of resins employed in Fmoc-SPPS synthesis has been described.

It is therefore an object of the present invention to provide solid support resins for Fmoc-SSPPS synthesis which are applicable for all 20 of the naturally occurring L-amino acids, the unnatural D-amino acids, and for any other molecule which contains a carboxylic acid moiety.

It is another object of the present invention to provide a solid support resin for Fmoc-solid phase peptide synthesis which results in high yield of synthetic polypeptides.

Another object of the present invention is to provide solid support resins for Fmoc-solid phase peptide synthesis which eliminates undesirable side reactions during the attachment of the first amino acid to the solid support matrix.


Yet another object of the present invention is to provide solid support resins for Fmoc-solid phase peptide synthesis which requires a decreased amounts of solvent in the washing steps during the peptides building processes compared to prior art resins.

Yet another object of the present invention is to provide solid support resins for Fmoc-solid phase peptide synthesis which are relatively inexpensive and easy to manufacture.

The invention possesses other objects and advantages especially as concerns particular characteristics and features thereof which will be apparent as the specification continues.


DESCRIPTION OF THE PREFERRED EMBODIMENTS

Resin #1 may be prepared by adding the Merrifield resin of the prior art to the vanillyl alcohol or a derivative thereof by the following reaction:



The R with a circle around it indicates a styrene-divinylbenzene copolymer in a gel form or a pellicular form which is suitable for flow synthesis.


Resin #1 may be represented by the following formulae:



where: "n" is the basic unit of the resin matrix, R is a methyl, ethyl, or lower alkyl group having (7) carbons or less. R may also stand for methoxy, ethoxy, or lower alkoxy group having (7) carbons or less.


Treating the above resin with an Fmoc-amino acid group loads or derivatizes the subject resin. Such addition takes place in the presence of carbonyldiimidazol (CDI) and DCM. The product is collected by filtration after an incubation period. The following formulae represents the

derivatized resin #1.




where "n" is the basic unit of the resin matrix, R¹ an alky or alkoxy group, and where R² is an amino acid moiety or other carboxylic acid containing molecule. It has been discovered that the derivatized HMBA resin (Resin #1) may be cleaved using 25% TFA in DCM which achieves a significant improvement over the 95% TFA required by the prior art, in that undesirable side reactions are virtually eliminated.

Resin #2 is formed by the reaction between polystyrene-dvb copolymer and benzoyl chloride in the presence of aluminum chloride and dichloroethane (DCE) to produce a keto resin. Such resin is then formed into an alcohol by a Grignard reaction in the presence of tetrahydrofuran (THF) according to the following reaction:




Resin #2 is a very dilute acid susceptible resin which

may be employed for the production of protected peptide fragments by Fmoc-SPPS. 15% acetic acid in 85% DCM, rather than TFA, may be used to cleave the finished protected peptides from the support matrix. Resin #2 may be shown by the following formula:




where "n" is the basic unit of the resin matrix, R_1 , R_2 , R_3 , and/or R_4 is either hydrogen, methyl, ethyl, or lower alkyl groups of (7) carbons or less, methoxy, ethoxy, or lower alkoxy groups of (7) carbons or less. In its derivatized or loaded form, resin 2 may be represented by the formula:




where R_5 is an amino acid moiety or other carboxylic acid containing molecule. It should be noted that the alcohol functional group of Resin #2 must be converted to a chloride prior to loading, which will be described in detail hereinafter.

Resin #3 is used specifically for the production of peptide amides by Fmoc-SPPS and is prepared according to the following reaction where a trityl chloride resin is


converted to the trityl amine resin (Resin #3) in the presence of anhydrous ammonia and DCM:



It should be noted that the trityl chloride resin shown above may be gathered from the derivatization process with respect to resin #2 under the following reaction by treating trityl alcohol resin with acetylchloride in the presence of DCM:




The trityl chloride resin may be loaded with the Fmoc-amino acid group or converted to the trityl amine resin above shown. The trityl amine resin (Resin #3) may be presented by the following formula:



where "n" is the basic unit of the resin matrix, R₁, R₂, R₃, and/or R₄, are hydrogen, methyl, ethyl or other lower alkyl group, with less than (7) carbons, methoxy, ethoxy or other lower alkoxy group, with less than (7) carbons.

In its derivatized or loaded state, resin #3 may be

represented by the following formula:



where R_5 is an amino acid moiety or other carboxylic acid containing molecule.

The present invention is illustrated by the following examples, but is not deemed to be restricted thereby. Abbreviations appearing therein are ones normally used in the field of solid phase peptide synthesis.

EXAMPLE 1

This example describes the production, derivatization and cleavage of resin #1 hereinbefore described.

6.0 gm of chloromethylated polystyrene-DVB copolymer at 4.15 meq of chloride per gram of resin was swollen in 50ml of either dimethylacetamide (DMA) or dimethylformamide (DMF). 11.24gm of 4-hydroxy-3-methoxy benzyl alcohol (HMBA or vanillyl alcohol) was dissolved in 20ml of DMA. This solution was added to the swollen resin and mixed. 3.94gm of sodium methoxide was then added to the suspension and incubated at 65° C for 8 hours and then steadily mixed overnight at room temperature. The resulting HMBA resin was collected by filtration, washed with DMF, twice with dichloromethane (DCM), once with methanol, and again, twice with DCM. The washed filtrate was dried in an oven at 45° Centigrade. The resulting yield was 11.63gm of derivitized HMBA resin which calculated to a weight gain of 5.63gm. It was determined that 36.5 mmoles of the HMBA was attached to the polystyrene-DVB copolymer. Thus, the final product included 2.7mmole/gm of functional units. 1.0gm of this product was loaded using exemplar Fmoc-phenylalanine as

follows. 2.0gm of carbonyldiimidazol (12.3mmole) was dissolved with 2.6gm of Fmoc-phenylalanine (6.7mmole) in 10ml of DCM, mixed thoroughly, and preincubated at room temperature for 10-15 minutes. This mixture was then added the HMBA resin, and the suspension was incubated overnight at room temperature (21° C). The product was then collected by filtration, washed twice with DCM, once with methyl alcohol, twice with DCM, and dried in an oven at 35° C. The level of substitution was determined on a 10mg sample of the product by cleaving off the Fmoc group with 1.0ml of 20% pyrrolidine in DCM, filtering off the resin, and diluting the volume to 10ml. The optical density of a 1:10 dilute sample was then measured. This figure was then divided by the molar extension coefficient $\times 10^{-3}$. The resulting value represents the mmole/gm of Fmoc-amino acid attached to the resin and equals the level of substitution achieved. In this illustrative portion of Example I, 1.24mmole of Fmoc-phenylalanine per gram of resin was achieved. The following Table I illustrates the level of substitution achieved with other Fmoc-amino acids using similar techniques to the above described technique employed with Fmoc-phenylalanine.

TABLE I
Loading of HMBA resin (Resin #1) with Fmoc-Amino Acids

<u>Fmoc-Amino Acid</u>	<u>Level of Substitution</u>
	<u>Achieved in mmole/gm</u>
Fmoc-Ala	0.84, 0.69 & 0.50
Fmoc-Gly	0.68, 0.52 & 0.73
Fmoc-Gln(Trt)	0.35
Fmoc-Glu(o-t-But)	0.34
Fmoc-Leu	0.55, 0.27, 1.36 & 0.83
Fmoc-Phe	1.24 & 0.69
Fmoc-Pro	0.47
Fmoc-Ser(o-t-But)	0.70 & 0.39
Fmoc-Tyr(o-t-But)	0.49
Fmoc-Val	0.77 & 0.43

The loaded resins above identified can be used in

Fmoc-SPPS and the cyclic additions of amino acids through the use of preformed symmetric anhydrides, DIPCDI/HOBt, BOP/HOBt or various other coupling methods. Subsequent to building the desired peptide sequence, peptide (with a free carboxyl terminal) is cleaved from the support resin by treating the peptide-resin with 100ml of 25% TFA in DCM per mmole of peptide. The following Table II illustrates the time course for cleavage of various Fmoc-amino acids from the support resin. The free synthetic peptide is isolated and used as desired.

TABLE II
Cleavage of Fmoc-Amino Acids from HMBA Resin with 25%
TFA.

<u>Fmoc-Amino Acid</u>	<u>Length of Incubation</u>	<u>Mmole/gm</u>
Fmoc-Leu	10 min.	0.22
	20 min.	0.22
	30 min.	0.28
	60 min.	0.38
	120 min.	0.23
Fmoc-Val	10 min.	0.36
	20 min.	0.36
	30 min.	0.32
	60 min.	0.42
	120 min.	0.45
Fmoc-Gln(Trt)	10 min.	0.25
	20 min.	0.30
	30 min.	0.26
	60 min.	0.24
	120 min.	0.28

EXAMPLE 2

Production, derivitization, and cleavage of resin #2 (trityl alcohol resin).

50gm of polystyrene-DVB copolymer was swollen in 400ml of dichloroethane (DCE) or DCM and the suspension chilled to -6°C. 56mm of benzoyl chloride and 64gm of aluminum chloride were suspended in 100ml of the same solvent and added dropwise to the suspended resin with constant mixing.

After the dropwise addition was completed, the suspension was allowed to come to room temperature and the keto resin formation continued overnight with constant mixing. The resulting keto-resin was collected by filtration, washed twice with DCM, once with methanol, again, twice with DCM and dried in an oven at 45° C. The yield was 82 grams of keto-resin at 3.75mmole/gm. 5gm of keto-resin was suspended in 50ml of tetrahydrofuran (THF) and 15ml of 3M phenylmagnesium bromide in ether was added to the suspension with constant mixing. The Grignard reaction was incubated overnight at room temperature to yield trityl alcohol resin (Resin #2) which was collected by filtration, washed twice with DCM, once with methanol, again, twice with DCM, and dried in an oven at 35° C. The trityl alcohol resin is then converted to a chloride prior to loading. The dried trityl alcohol resin from the Grignard reaction was swollen in 50ml of toluene and 10ml of acetyl chloride (140mmole) was added and incubated overnight at room temperature to convert the functional group from a hydroxyl to a chloride. The trityl chloride resin was collected by filtration washed and dried as the trityl alcohol resin hereinbefore. To load the trityl chloride resin 3 grams of the same was employed. 3.87gm of Fmoc-phenylalanine (10mmole) or other carboxylic acid containing molecule and an equivalent amount of diisopropylethylamine (DIEA) dissolved in DCM was added, and the suspension incubated overnight at room temperature (21° C). The product was collected by filtration washed and dried in the same manner as the trityl alcohol resin hereinbefore described. The level of substitution was determined on a 10mg sample by cleaving off the Fmoc group with 1.0ml of 20% pyrrolidine in DCM, filtering off the resin, adjusting the volume to 10ml measuring the optical density of a 1:10 dilute sample and dividing the OD by the molar extinction coefficient $\times 10^{-3}$. The resulting quantity represents the mmole per gram of Fmoc-amino acid attached to the resin and, thus, equals the level of substitution achieved.

Table III below illustrates the level of substitution achieved with various Fmoc amino acids using resin #2:

TABLE III

Loading of Trityl Alcohol Resin (Resin #2) with Fmoc-Amino Acids.

<u>Fmoc-Amino Acid</u>	<u>Level of Substitution</u> <u>Achieved in mmole/gm</u>
Fmoc-Ala	0.41
Fmoc-Cys(Trt)	0.95
Fmoc-Cys(Acm)	0.46
Fmoc-Asp(o-t-But)	0.95
Fmoc-Glu(o-t-But)	0.34
Fmoc-Phe	0.95 & 0.62
Fmoc-Gly	0.80, 1.00 & 0.60
Fmoc-His(Trt)	0.81
Fmoc-Ile	1.03
Fmoc-Lys(Boc)	0.85
Fmoc-Leu	0.88 & 0.79
Fmoc-Met	0.83
Fmoc-Asn	0.76
Fmoc-Asn(Trt)	0.65
Fmoc-Pro	0.84
Fmoc-Gln	0.53
Fmoc-Gln(Trt)	0.42
Fmoc-Arg(Mtr)	0.31
Fmoc-Arg(Pmc)	0.31
Fmoc-Ser(o-t-But)	0.85
Fmoc-Thr(o-t-But)	0.85
Fmoc-Val	0.91
Fmoc-Trp	0.66
Fmoc-Tyr(o-t-But)	0.82

The derivatized or loaded resin was then ready for use in Fmoc-SPPS and the cyclic addition of amino acids using preformed symmetric anhydrides with an equivalent of DIEA or BOP/HOBt/DIEA coupling. Various amino acids were attached and cleaved from the support resin by treatment of the peptide-resin with 200ml of 15% acetic acid and DCM per

mole of peptide. Table IV illustrates the time course for cleavage of various Fmoc-amino acids from the support resin.

TABLE IV

<u>Fmoc-Amino Acid</u>	<u>Length of Incubation</u>	<u>Mmole/gm</u>
Fmoc-Phe	10 min.	0.67
	20 min.	0.59
	30 min.	0.59
	60 min.	0.61
	120 min.	0.60
Fmoc-Leu	10 min.	0.83
	20 min.	0.67
	30 min.	0.66
	60 min.	0.78
	120 min.	0.75
Fmoc-Gly	10 min.	0.60
	20 min.	0.54
	30 min.	0.59
	60 min.	0.74
	120 min.	0.52

EXAMPLE 3

Production, Derivatization, and Cleavage of Resin #3-Triptylamine Resin.

The triptyl chloride resin produced and described in Example II was used as the starting material. The chloride group was converted to a amine group by swelling the triptyl chloride resin in DCM and anhydrous ammonia was bubbled through the suspension overnight. The triptyl amine resin was collected by filtration, washed, and dried according to the process described in Example II. 1.0gm of the triptyl amine resin was loaded with Fmoc amino acids. As an example, 3.1 grams of Fmoc-phenylalanine (8.0 mmole), an equivalent amount of diisopropylcarbodiimide (DIPCDI), and an equivalent amount of hydroxybenzotriazole (HOBr) were added together, dissolved in DMF, and the resulting

suspension incubated 4-6 hours at room temperature (21° C). The product was collected by filtration, washed, and dried by the process heretofore described. The level of substitution was determined on a 10mg sample by cleaving off the Fmoc group with 1.0ml of 20% pyrrolidine in DCM, filtering off the resin, adjusting the volume to 10ml, and measuring the optical density (OD) of a 1:10 dilute sample, and dividing the OD by the molar extinction coefficient $\times 10^{-3}$. The resulting number represents the mmole/gm of Fmoc-amino acid attached to the resin and equals the level substitution achieved. Table V illustrates the level of substitution achieved with various Fmoc-amino acids prepared by using resin #3:

TABLE V
Loading of Trityl Amine Resin (Resin #3) with Fmoc-Amino Acids.

<u>Fmoc-Amino Acid</u>	<u>Level of Substitution Achieved in mmole/gm</u>
Fmoc-Met	0.15
Fmoc-Phe	1.30
Fmoc-Pro	0.35
Fmoc-Asn	0.71

Again such loaded resins can be used in Fmoc-SPPS and the cyclic addition of amino acids using methods heretofore described in Examples I and II. Peptide sequences built using the resin of this Example were cleaved from the support resin by treating the peptide resin with 100ml of 25% TFA in DCM per mmole of peptide. The cleaved entity is a free peptide with a carboxyl amide terminal. Table VI illustrates the time course for cleavage of various Fmoc-Amino Acid-Amides from the support resin.

TABLE VI
Cleavage of Fmoc-Amino Acid Amides from Trityl Amine Resin with 25° TFA in DCM.

<u>Fmoc-Amino Acid</u>	<u>Length of Incubation</u>	<u>Mmole/gm</u>
Fmoc-Pro-NH ₂	10 min.	0.19
	20 min.	0.13
	30 min.	0.19
	60 min.	0.19
	120 min.	0.16
Fmoc-Asn-NH ₂	10 min.	0.88
	20 min.	0.62
	30 min.	0.75
	60 min.	0.42
	120 min.	0.39

EXAMPLE 4

Employing resin #1 of Example I (HMBA Resin), a 12mer having the following formula was built:

Ac-Tyr-Cys-Ala-Pro-Leu-Lys-Pro-Ala-Lys-Ser-Ala

200 mgm of Fmoc-Ala-HMBA resin, of Example 1 at a level of substitution of 0.5 mmole/gm (0.1 mmole of substituted resin) was used. The remaining eleven amino acids of the present 12 mer were added in cyclic fashion. The addition of each Fmoc-Amino Acid was achieved using a four fold molar excess of the individual Fmoc-Amino Acids, HOBt, and DIPCDI during coupling cycle. The Fmoc-protecting group was removed using 20% pyrrolidine in DMF during the deprotection step of each cycle. After the amino terminal tyrosine was deprotected, the amino terminus was acetylated using acetic anhydride and triethylamine. The synthetic peptide was cleaved from support resin and the side chains of the trifunctional amino acids were deprotected simultaneously by treating the peptide-resin with 25% TFA, 4% water and DTT in DCM. The crude peptide was partially purified by gel filtration in 25% acetic acid and yielded 126mgm of peptide. Based on a molecular weight of 1208.6, the yield of peptide was 104.2%. The partially pure peptide was purified to homogeneity by preparative HPLC, which yielded 82.5 mgm of pure peptide (68.3% overall yield). Amino acid analysis of the peptide yielded the

following results shown in Table VII below.

TABLE VII

<u>Residue</u>	<u>Theory</u>	<u>Found</u>
Ala	3	2.9
Tyr	1	1.0
Lys	2	2.0
Pro	2	2.0
Cys	1	present
Ser	1	0.9
Ileu	1	1.0

EXAMPLE 5

Utilizing the HMBA resin of Example I (Resin #1) the following peptide was constructed:

Ser-Tyr-Thr-Asn-Pro-Glu-Phe-Val-Ile-Asn-Val

465 mgm of Fmoc-Val-HMBA resin at a level of substitution of 0.43 mmole/gm (0.2mmole of substituted resin) was employed. The cyclic addition of each Fmoc-amino acid was achieved using a four-fold molar excess of the individual Fmoc-amino acids, HOBr, and DIPCDI during each coupling cycle. The Fmoc protecting group was removed using 20% pyrrolidine in DMF during the deprotection step of each cycle. The peptide was cleaved from the support resin and the side chains of the trifunctional amino acids were deprotected simultaneously by treating the peptide-resin with 25% TFA, 4% water, and 1% DTT in DCM. The crude peptide was partially purified by gel filtration in 25% acetic acid and yielded 256 mgm of peptide. Based on a molecular weight of 1282.3, the yield was 99.8%. The partially pure peptide was purified to homogeneity by preparative HPLC and yielded 119 mgm of pure peptide (46.4% overall yield). Amino acid analysis of the peptide yielded the following results which is represented in Table VIII below.

TABLE 6

<u>Residue</u>	<u>Theory</u>	<u>Found</u>
Asx	2	2.1

19

Glx	1	1.0
Tyr	1	1.0
Thr	1	0.9
Pro	1	1.0
Ile	1	1.1
Phe	1	1.0
Ser	1	0.9
Val	2	2.0

EXAMPLE 6

Utilizing the HMBA resin (Resin 1) of Example I, the following peptide was constructed:

Ser-Phe-Val-Asn-Ser-Glu-Phe-Leu-Lys-Pro-Glu-Val-Lys-Ser

384 mgm of Fmoc-Ser(o-t-But)-HMBA resin at 0.39 mmole/gm (0.15 mmole of substituted resin) was used. The cyclic addition of each Fmoc-amino acid was achieved using a four fold molar excess of the individual Fmoc-amino acids, HOBT, and DIPCDI during each coupling cycle. The Fmoc protecting group was removed using 20% pyrrolidine in DMF during the deprotection step of each cycle. The peptide was cleaved from the support resin and the side chains of the trifunctional amino acids were deprotected simultaneously by treating the peptide-resin with 25% TFA, 4% water, and 1% DTT in DCM. The crude peptide was partially purified by gel filtration in 25% acetic acid and yielded 231 mgm of peptide. Based on a molecular weight of 1610.9, the yield was 95.6%. The partially pure peptide was purified to homogeneity by preparative HPLC and yielded 172 mgm of pure peptide (70.9% overall yield). Amino acid analysis of the peptide yielded the following results which is shown in Table IX:

TABLE IX

<u>Residue</u>	<u>Theory</u>	<u>Found</u>
Asx	1	1.0
Glx	2	1.9
Lys	2	2.0
Pro	1	1.0

20

Phe	2	2.0
Ser	3	2.6
Val	2	2.1
Leu	1	1.0

EXAMPLE 7

The following protected peptide was constructed using the trityl alcohol resin of Example II (Resin 2):

Fmoc-Cys(Trt)-Ser(o-t-But)-Asn-Leu-Ser(o-t-But)-Thr(o-t-But)-Cys(Trt)-Val-Leu-Gly

100 mgm of Fmoc-Gly-Trityl resin at 1.00 mmole/gm (0.1 mmole of substituted resin) was used. The cyclic addition of each Fmoc-amino acid was achieved using an equivalent HOBT, a three fold molar excess of the individual Fmoc-amino acids and BOP, and a 6 fold molar excess of DIEA during each coupling cycle. The Fmoc-protecting group was removed using 20% pyrrolidine in DMF during the deprotection step of each cycle. However, the last Fmoc protecting group on the amino acid terminal residue was not removed. Therefore, the amino terminus as well as all the side chains of the trifunctional amino acids were still protected when the synthesis of this peptide was complete. The fully protected peptide was cleaved from the support resin with 15% acetic acid in DCM. The protected peptide was collected, the acetic acid extracted into water 3 times, the solvent removed by rotary evaporation, and the product dried over P_2O_5 under vacuum. 165 mgm of protected peptide was recovered. Based on a molecular weight of 1805.0 for the fully protected peptide, the yield was 91.4%. A sample of the protected peptide is treated with 20% pyrrolidine in DCM to remove the Fmoc-protecting group, and the sample was hydrolyzed for amino acid analysis. Amino acid analysis of the sample yielded the following results which is shown in Table X.

TABLE X

<u>Residue</u>	<u>Theory</u>	<u>Found</u>
Asx	1	1.0

21

Thr	1	0.9
Cys	2	present
Ser	2	1.8
Gly	1	1.0
Val	1	1.0
Leu	2	2.1

EXAMPLE 8

The following peptide was constructed using the Trityl alcohol resin of Example II (Resin 2):

Fmoc-Glu(o-t-But)-Thr(o-t-But)-Leu-Pro-Gln-Gly

200 mgm of Fmoc-Gly-Trityl resin at 1.0 mmole/gm (0.2 mmole of substituted resin) was used. The cyclic addition of each Fmoc-amino acid was achieved using an equivalent of HOBT, a three fold molar excess of the individual Fmoc-amino acids and BOP, and a six fold molar excess of DIEA during each coupling cycle. The Fmoc-protecting group was removed using 20% pyrrolidine in DMF during the deprotection step of each cycle. However, the last Fmoc-protecting group on the amino terminal residue was not removed. Therefore, as with Example VII, the amino terminus as well as all the side chains of the trifunctional amino acids were still protected when synthesis of the peptide was complete. The fully protected peptide was cleaved from the support resin with 15% acetic acid in DCM. The protected peptide was collected, the acetic acid extracted into water 3 times. The solvent was removed by rotary evaporation and the product dried over P_2O_5 under vacuum. 177 mgm of protected peptide was recovered. Based on a molecular weight of 960.8 for the fully protected peptide, the yield was 92.2%. A sample of the protected peptide was treated with 20% pyrrolidine in DCM to remove the Fmoc-protecting group, and the sample hydrolyzed for amino acid analysis. The amino acid analysis yielded the following results which is shown in Table XI.

TABLE XI

<u>Residue</u>	<u>Theory</u>	<u>Found</u>
Glx	2	2.0
Thr	1	0.9
Pro	1	1.0
Gly	1	1.0
Leu	1	1.0

EXAMPLE 9

Employing the Trityl Amine resin of Example III (Resin #3) the following peptide was constructed:



170 mgm of Fmoc-Met-Trityl Amine resin at 0.15 mmole/gm (0.025 mmole of substituted resin) was used. The cyclic addition of each Fmoc-amino acid was achieved using a four fold molar excess of the individual Fmoc-amino acids, HOBT and DIPCDI during each coupling cycle. The Fmoc-protecting group was removed using 20% pyrrolidine in DMF during the deprotection step of each cycle. The peptide was cleaved from the support resin and the side chains of the trifunctional amino acids were deprotected simultaneously by treating the peptide-resin with 25% TFA, 4% water, and 1% DTT in DCM. The crude peptide was partially purified by gel filtration in 25% acetic acid and yielded 24 mgm of peptide. Based on a molecular weight of 1010.4, the yield was 95%. The partially pure peptide was purified to homogeneity by preparative HPLC and yielded 20 mgm of pure peptide (79.2% overall yield). Amino acid analysis yielded the following result is shown in the following Table XII:

TABLE XII

<u>Residue</u>	<u>Theory</u>	<u>Found</u>
Glx	1	1.0
Met	1	1.0
Tyr	1	1.0
Lys	2	2.0
Ser	1	0.9
Leu	2	2.0

EXAMPLE 10

The following peptide was constructed utilizing the Trityl Amine resin of Example III (Resin 3): Phe-Met-Arg-Phe-NH₂

260 mgm of Fmoc-Phe-Trityl Amine resin at 1.30 mmole/gm (0.20 mmole of substituted resin) was used. The cyclic addition of each Fmoc-amino acid was achieved using a four fold molar excess of the individual Fmoc-amino acids, HOBT and DIPCDI during each coupling cycle. The Fmoc-protecting group was removed using 20% pyrrolidine in DMF during the deprotection step of each cycle. The peptide was cleaved from the support resin with 25% TFA and 1.0% DTT in DCM for 60 minutes. The crude peptide was then treated with 50% TFA and 10% thioanisole in DCM overnight to remove the Pmc blocking group from the side chain of arginine. The peptide was partially purified by gel filtration in 25% acetic acid and yielded 122 mgm of peptide. Based on a molecular weight of 598.8, the yield was 101.8%. The partially pure peptide was purified to homogeneity by preparative HPLC and yielded 107 mgm of pure peptide (89.3% overall yield). Amino acid analysis yielded the following results which is shown by Table XIII below.


TABLE XIII

<u>Residue</u>	<u>Theory</u>	<u>Found</u>
Met	1	1.0
Phe	2	2.0
Arg	1	1.0

While in foregoing, embodiments of the present invention have been set forth in considerable detail for the purposes of making a complete disclosure of the invention, it may be apparent to those of skill in the art that numerous changes may be made in such detail without departing from the spirit and principles of the invention.

WHAT IS CLAIMED IS

1. A polymeric resin suitable for use in peptide synthesis consisting essentially of the formulae:



where "n" is the basic unit of the resin matrix, R is an alkyl or alkoxy group.


2. The polymer resin of claim 1 in which R is a methoxy group and the polymer and the polymer matrix is polystyrene- divinylbenzene copolymer.

3. The polymeric resin of claim 1 in which R is a lower alkoxy group and the polymer matrix is a polystyrene- divinylbenzene copolymer.

4. The polymeric resin of claim 1 in which R is a methyl group and the polymer matrix is a polystyrene- divinylbenzene copolymer.

5. The polymeric resin of claim 1 in which R is a lower alkyl group and the polymer matrix is polystyrene- divinylbenzene.


6. A derivatized polymeric resin suitable for use in peptide synthesis comprising essentially of the formulae:



where "n" is the basic unit of the resin matrix, R¹ is an alkyl or alkoxy group and where R² is an amino acid moiety or other carboxylic acid containing molecule.

7. The derivatized polymeric resin of claim 6 in which R² is an amino acid moiety or carboxylic acid containing molecule linked to a protecting group.

8. A polymeric resin suitable for use in peptide synthesis consisting essentially of the formulae:




where "n" is the basic unit of the resin matrix, R₁, R₂, R₃, and R₄ are selectively hydrogen, an alkoxy, and an alkyl group.

9. The polymeric resin of claim 8 in which the polymer matrix is polystyrene cross-linked with divinylbenzene.

10. The polymeric resin of claim 9 in which R₁, R₂, R₃ and R₄ are each hydrogen.

11. A derivatized polymeric resin suitable for use in peptide synthesis consisting essentially of the formulae:




where "n" is the basic unit of the resin matrix, R₁, R₂, R₃ and R₄ are selectively hydrogen, an alkoxy, and an alkyl group and R₅ is an amino acid moiety or a carboxylic acid

group.

12. The derivatized polymeric resin of claim 11 in which R_1 , R_2 , R_3 , and R_4 are each hydrogen and R_5 is an amino acid moiety or a carboxylic acid containing molecule linked to a protecting group.

13. A polymeric resin suitable for use in peptide synthesis consisting essentially of the formulae:




where "n" is the basic unit of the resin matrix, R_1 , R_2 , R_3 , R_4 are selectively hydrogen, an alkoxy, and an alkyl group.

14. The polymeric resin of claim 13 in which the polymer is polystyrene cross-linked with divinylbenzene.

15. The polymeric resin of claim 13 in which R_1 , R_2 , R_3 and R_4 are each hydrogen.


16. A derivatized polymeric resin suitable for use in peptide synthesis consisting essentially of the formulae:



where "n" is the basic unit of the resin matrix, R_1 , R_2 , R_3 and R_4 are selectively hydrogen, an alkyl, and an alkoxy group.

17. The derivatized polymeric resin of claim 17 in which R_1 , R_2 , R_3 , and R_4 are selectively hydrogen and R_5 is an amino acid moiety or a carboxylic acid group linked to a protecting group.


18. A polymeric resin suitable for use in peptide synthesis consisting essentially of the formulae:



where "n" is the basic unit of the resin matrix, R_1 , R_2 , R_3 , and R_4 are selectively hydrogen on alkoxy and an alkyl group.

19. A method of synthesizing a peptide comprising the steps of:

a. providing a derivatized polymeric resin having the formulae:




where "n" is the basic unit of the resin matrix, R^1 is an alkyl or alkoxy group, R^2 is an amino acid moiety and R^3 is a protecting group;

b. cleaving the protecting group from the amino acid moiety; and

c. coupling an amino acid having a protected amino terminal group to the R² group.

20. A method of synthesizing peptide comprising the steps of:

a. providing a derivatized polymeric resin having the formulae:




where R¹ is an amino acid moiety and R² is a protecting group;

b. cleaving the protecting group from the amino acid moiety; and

c. coupling an amino acid having a protected amino terminal group to the R¹ group.

21. A method of synthesizing peptide comprising the steps of:

a. providing a derivatized polymeric resin having the formulae:



where R¹ is an amino acid moiety and R² is a protecting group;

b. cleaving the protecting group from the amino acid moiety; and

c. coupling an amino acid having a protected

amino terminal group to the R¹ group.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US92/05046

A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) :C08F 8/14, 8/30; C07L 29/02, 29/10

US CL :525/328.8, 328.9, 332.2; 526/332,333,334,336

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. :

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONEElectronic data base consulted during the international search (name of data base and, where practicable, search terms used)
NONE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US.A, 4,085,261, (PATCHORNICK ET AL.), 18 APRIL 1978.	1-10
A	US.A, 3,954,709 (STEWART ET AL), 04 MAY 1976.	1-10
A	US.A, 3,814,732 (WANG), 04 JUNE 1974.	1-10
A	US.A, 3,743,628 (BODANSZKY), 03 JULY 1973	1-10
A	US.A, 3,645,996 (SOUTHARD), 29 FEBRUARY 1972	1-10

 Further documents are listed in the continuation of Box C. See patent family annex.

Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be part of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

03 SEPTEMBER 1992

Date of mailing of the international search report

29 OCT 1992

Name and mailing address of the ISA/
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. NOT APPLICABLE

Authorized officer

BERNARD LIPMAN

Telephone No. (703) 308-2351